Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 21 studies | 30% ± 10% | |
astrocyte | 11 studies | 27% ± 13% | |
microglial cell | 11 studies | 30% ± 8% | |
oligodendrocyte precursor cell | 11 studies | 37% ± 13% | |
glutamatergic neuron | 10 studies | 52% ± 26% | |
macrophage | 10 studies | 35% ± 13% | |
oligodendrocyte | 10 studies | 23% ± 9% | |
adipocyte | 9 studies | 38% ± 11% | |
fibroblast | 9 studies | 26% ± 11% | |
GABAergic neuron | 8 studies | 40% ± 23% | |
epithelial cell | 8 studies | 33% ± 13% | |
type I pneumocyte | 7 studies | 38% ± 18% | |
interneuron | 6 studies | 38% ± 22% | |
myeloid cell | 6 studies | 25% ± 7% | |
T cell | 6 studies | 30% ± 8% | |
endothelial cell of lymphatic vessel | 6 studies | 38% ± 15% | |
neuron | 5 studies | 36% ± 15% | |
dendritic cell | 5 studies | 25% ± 5% | |
ciliated cell | 5 studies | 30% ± 11% | |
monocyte | 5 studies | 39% ± 6% | |
pericyte | 5 studies | 29% ± 9% | |
smooth muscle cell | 5 studies | 22% ± 3% | |
type II pneumocyte | 5 studies | 32% ± 12% | |
B cell | 4 studies | 25% ± 7% | |
cardiac muscle cell | 4 studies | 29% ± 4% | |
lymphocyte | 4 studies | 35% ± 18% | |
alveolar macrophage | 4 studies | 42% ± 20% | |
club cell | 4 studies | 34% ± 13% | |
basal cell | 4 studies | 31% ± 18% | |
classical monocyte | 3 studies | 20% ± 5% | |
GABAergic interneuron | 3 studies | 30% ± 7% | |
granule cell | 3 studies | 26% ± 9% | |
CD4-positive, alpha-beta T cell | 3 studies | 30% ± 2% | |
CD8-positive, alpha-beta T cell | 3 studies | 26% ± 5% | |
mesothelial cell | 3 studies | 37% ± 12% | |
vein endothelial cell | 3 studies | 42% ± 23% | |
endothelial cell of vascular tree | 3 studies | 32% ± 18% | |
hepatocyte | 3 studies | 46% ± 21% | |
connective tissue cell | 3 studies | 20% ± 3% | |
ependymal cell | 3 studies | 28% ± 10% | |
natural killer cell | 3 studies | 31% ± 2% | |
respiratory goblet cell | 3 studies | 32% ± 13% | |
leukocyte | 3 studies | 45% ± 10% | |
mucus secreting cell | 3 studies | 28% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3156.94 | 1445 / 1445 | 100% | 17.97 | 183 / 183 |
lung | 100% | 3618.25 | 578 / 578 | 100% | 19.24 | 1152 / 1155 |
breast | 100% | 3918.88 | 459 / 459 | 100% | 24.00 | 1113 / 1118 |
prostate | 100% | 2879.71 | 245 / 245 | 99% | 16.83 | 499 / 502 |
intestine | 100% | 2831.17 | 966 / 966 | 99% | 14.31 | 523 / 527 |
thymus | 100% | 2681.69 | 653 / 653 | 99% | 18.43 | 600 / 605 |
bladder | 100% | 2667.67 | 21 / 21 | 99% | 13.87 | 498 / 504 |
kidney | 100% | 2432.89 | 89 / 89 | 99% | 19.09 | 890 / 901 |
brain | 99% | 2001.87 | 2605 / 2642 | 100% | 13.73 | 705 / 705 |
uterus | 100% | 5199.17 | 170 / 170 | 98% | 17.39 | 452 / 459 |
ovary | 100% | 2552.92 | 180 / 180 | 98% | 18.13 | 423 / 430 |
stomach | 100% | 2273.35 | 359 / 359 | 98% | 14.81 | 280 / 286 |
pancreas | 98% | 1425.54 | 323 / 328 | 99% | 15.40 | 176 / 178 |
adrenal gland | 100% | 2385.52 | 258 / 258 | 91% | 6.95 | 209 / 230 |
skin | 100% | 2988.47 | 1807 / 1809 | 91% | 13.32 | 428 / 472 |
liver | 99% | 1280.26 | 223 / 226 | 91% | 8.84 | 371 / 406 |
blood vessel | 100% | 3117.61 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 13.76 | 29 / 29 |
muscle | 100% | 8387.38 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2608.72 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.80 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.52 | 1 / 1 |
adipose | 100% | 4513.10 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 95% | 2403.72 | 817 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 90% | 2039.96 | 837 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 80% | 6.79 | 64 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0071108 | Biological process | protein K48-linked deubiquitination |
GO_1902883 | Biological process | negative regulation of response to oxidative stress |
GO_1903882 | Biological process | negative regulation of interleukin-17-mediated signaling pathway |
GO_0031647 | Biological process | regulation of protein stability |
GO_0070536 | Biological process | protein K63-linked deubiquitination |
GO_0036211 | Biological process | protein modification process |
GO_0006508 | Biological process | proteolysis |
GO_1904293 | Biological process | negative regulation of ERAD pathway |
GO_0016579 | Biological process | protein deubiquitination |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0008233 | Molecular function | peptidase activity |
GO_0101005 | Molecular function | deubiquitinase activity |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0019783 | Molecular function | ubiquitin-like protein peptidase activity |
GO_0032183 | Molecular function | SUMO binding |
GO_0051117 | Molecular function | ATPase binding |
GO_0005515 | Molecular function | protein binding |
GO_0043130 | Molecular function | ubiquitin binding |
Gene name | USP25 |
Protein name | Ubiquitin specific peptidase 25 Ubiquitin carboxyl-terminal hydrolase 25 (EC 3.4.19.12) (Deubiquitinating enzyme 25) (USP on chromosome 21) (Ubiquitin thioesterase 25) (Ubiquitin-specific-processing protease 25) ubiquitinyl hydrolase 1 (EC 3.4.19.12) |
Synonyms | USP21 |
Description | FUNCTION: Deubiquitinating enzyme that hydrolyzes ubiquitin moieties conjugated to substrates and thus, functions in various biological processes including inflammation, immune response . Modulates the Wnt/beta-catenin pathway by deubiquitinating and stabilizing tankyrases TNKS1 and TNKS2 . Regulates KEAP1-NRF2 axis in the defense against oxidative assaults by deubiquitinating KEAP1 and protecting it from degradation leading to degradation of the NRF2 transcription factor that is responsible for mounting an anti-oxidation gene expression program . Positively regulates RNA virus-induced innate signaling by interacting with and deubiquitinating ERLIN1 and ERLIN2 . In turn, restricts virus production by regulating cholesterol biosynthetic flux . Acts as a negative regulator of interleukin-17-mediated signaling and inflammation through the removal of 'Lys-63'-linked ubiquitination of TRAF5 and TRAF6 . Prevents the ubiquitination and degradation of TRAF3 to reduce the phosphorylation levels of JNK and P38, the secretion of IL-1B and to induce endotoxin tolerance . .; FUNCTION: The muscle-specific isoform (USP25m) may have a role in the regulation of muscular differentiation and function. |
Accessions | Q9UHP3 ENST00000285679.10 [Q9UHP3-2] ENST00000449491.1 Q96B65 ENST00000285681.6 [Q9UHP3-1] H7C1T8 ENST00000351097.9 ENST00000453553.1 H7C253 ENST00000400183.7 [Q9UHP3-3] |